A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 2021, 13: 4839. PMID: 34638323, PMCID: PMC8508147, DOI: 10.3390/cancers13194839.Peer-Reviewed Original ResearchPD-L1 expressionNeoadjuvant immunochemotherapyPrimary triple-negative breast cancerTriple-negative breast cancerPrecise predictive biomarkersImmunomodulatory subtypeNovel immunomodulatoryPrimary TNBCTNBC responsePCR ratePredictive biomarkersPrimary tumorIM subtypesBreast cancerImmunochemotherapyLarge cohortTNBCImmunohistochemistryPilot studySubtypesExpressionPCRDurvalumabPatientsCohort